Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8680619 | Alzheimer's & Dementia: Translational Research & Clinical Interventions | 2017 | 9 Pages |
Abstract
Abundant data support Aβ42 as a target for prophylactic or early-stage intervention therapies in AD. The γ-secretase modulator, NGP 555 is being actively developed in human clinical trials for the prevention of Alzheimer's disease with the overall aim to achieve an appropriate balance of potency/efficacy on reducing the toxic forms of amyloid versus safety.
Keywords
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Maria Z. Kounnas, Courtney Lane-Donovan, Dan W. Nowakowski, Joachim Herz, William T. Comer,